EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic and clinical determinants of outcome in Irish AML: a real-world analysis (2007–2025), single centre experience

Ezzat Elhassadi, Ellen O'Rourke, Ahmed Bannaga, Senthil Kumar, Brain Hennessy

Annals of Hematology · 30.05.2026 · 105 (8)

DOI: 10.1007/s00277-026-07081-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 30.05.2026. Verfasst von Ezzat Elhassadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Royal College Of Surgeons Ireland, University Hospital Waterford, Waterford, Ireland. ezzatelhassdi@rcsi.ie. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal College of Surgeons in Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukaemia (AML) is a genetically heterogeneous malignancy in which cytogenetic and molecular features critically inform diagnosis, prognosis, and therapeutic decision-making. While traditional karyotyping has long guided risk stratification, high-throughput sequencing has revealed extensive molecular diversity, particularly within cytogenetically normal AML, reshaping AML classification and management. This study characterises the genomic landscape and clinical outcomes of an Irish AML cohort using integrated cytogenetic and molecular profiling. We retrospectively analysed 166 adult AML patients diagnosed at our cancer centre between 2007 and 2025. Demographic, clinical, cytogenetic, molecular, and treatment data were collected. Karyotype-based and ELN 2022/2024 molecular classifications were applied. Survival analyses were performed using Prism v10.06, with statistical significance assessed using the log-rank (Mantel–Cox) test. Mutation frequencies were compared with published literature, and genomic subgroups were examined for prognostic impact. The median age at diagnosis was 70 years (range 24–92), with 68% de novo AML, 19% secondary AML, 10% therapy-related AML, and 3% APL. Of 126 treated patients, 72 received intensive therapy and 53 received less-intensive regimens. CR rates were 75% in the intensive cohort versus 36% in the less-intensive cohort. Karyotyping (available in 87%) revealed 47% with normal cytogenetics, favourable risk in 5% and 30% with adverse-risk features. Molecular profiling identified ELN 2022 adverse-, intermediate-, and favourable-risk categories in 42%, 47%, and 7% of intensively treated patients; in the less-intensive cohort, adverse risk predominated (87%). TP53 mutations occurred in 8% of the entire cohort. Median OS and PFS were 19 and 11 months, respectively. Younger age (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansFemaleMiddle AgedAgedMaleAdultRetrospective StudiesAged, 80 and overIrelandYoung AdultMutationGenomicsPrognosisTreatment Outcome

Stichwörter der Autor:innen

AMLELN risk stratificationKaryotypingMolecularTreatment outcome

Autor:innen und Institutionen

  • Department of Haematology, Royal College Of Surgeons Ireland, University Hospital Waterford, Waterford, Ireland. ezzatelhassdi@rcsi.ie.
  • Department of Haematology, Royal College Of Surgeons Ireland, University Hospital Waterford, Waterford, Ireland.

Förderung

  • Royal College of Surgeons in Ireland

Zitieren

APA

Elhassadi, E., O'Rourke, E., Bannaga, A., Kumar, S., & Hennessy, B. (2026). Genomic and clinical determinants of outcome in Irish AML: a real-world analysis (2007–2025), single centre experience. Annals of Hematology, 105(8). https://doi.org/10.1007/s00277-026-07081-2

Vancouver

Elhassadi E, O'Rourke E, Bannaga A, Kumar S, Hennessy B. Genomic and clinical determinants of outcome in Irish AML: a real-world analysis (2007–2025), single centre experience. Annals of Hematology. 2026;105(8). doi:10.1007/s00277-026-07081-2

BibTeX
@article{Elhassadi2026,
  author = {Elhassadi, Ezzat and O'Rourke, Ellen and Bannaga, Ahmed and Kumar, Senthil and Hennessy, Brain},
  title = {Genomic and clinical determinants of outcome in Irish AML: a real-world analysis (2007–2025), single centre experience},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {8},
  doi = {10.1007/s00277-026-07081-2}
}
Kostenlos starten →